Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BVXV

BiondVax Pharmaceuticals (BVXV) Stock Price, News & Analysis

BiondVax Pharmaceuticals logo

About BiondVax Pharmaceuticals Stock (NASDAQ:BVXV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.26
$1.59
52-Week Range
N/A
Volume
23,000 shs
Average Volume
127,289 shs
Market Capitalization
$2.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

SCNI Scinai Immunotherapeutics Ltd.
Trump Orders 'National Digital Asset Stockpile'
Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what could be the biggest wealth opportunity since Bitcoin's early days.
See More Headlines

BVXV Stock Analysis - Frequently Asked Questions

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) released its quarterly earnings data on Monday, March, 28th. The company reported ($2.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $1.80.

BiondVax Pharmaceuticals shares reverse split on the morning of Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

BiondVax Pharmaceuticals (BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that BiondVax Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP) and Pluristem Therapeutics (PSTI).

Company Calendar

Last Earnings
3/28/2022
Today
5/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BVXV
Employees
33
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($3.81) per share
Price / Book
N/A

Miscellaneous

Free Float
1,755,000
Market Cap
$2.54 million
Optionable
Not Optionable
Beta
2.37

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:BVXV) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners